S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

$2.89
+0.46 (+18.93%)
(As of 03/28/2024 ET)
Today's Range
$2.40
$2.97
50-Day Range
$1.91
$6.76
52-Week Range
$1.90
$14.29
Volume
951,900 shs
Average Volume
561,239 shs
Market Capitalization
$84.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Immuneering MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
436.3% Upside
$15.50 Price Target
Short Interest
Bearish
12.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.26mentions of Immuneering in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.89 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

139th out of 938 stocks

Pharmaceutical Preparations Industry

54th out of 420 stocks

IMRX stock logo

About Immuneering Stock (NASDAQ:IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Stock Price History

IMRX Stock News Headlines

3 Stocks Insiders Are Buying That Analysts Love
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Immuneering CEO acquires $55.3k in company stock
Immuneering Director Acquires 7.5% More Stock
Immuneering Appoints Thomas J. Schall, Ph.D.
See More Headlines
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$25.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+436.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-53,470,000.00
Pretax Margin
-5,163,499.50%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$3.09 per share

Miscellaneous

Free Float
22,548,000
Market Cap
$84.62 million
Optionable
Not Optionable
Beta
-0.75
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 42)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $898.42k
  • Mr. Robert J. Carpenter M.B.A. (Age 78)
    M.S., Co-Founder & Chair Emeritus
    Comp: $83.17k
  • Dr. Brett M. Hall Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $867.92k
  • Ms. Mallory Morales CPA (Age 40)
    Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Director of Accounting & Operations and Assistant Corporate Controller
  • Mr. Michael D. Bookman J.D. (Age 36)
    Chief Legal Officer & Secretary
  • Ms. Leah R. Neufeld (Age 52)
    Chief People Officer
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Praveen Nair Ph.D.
    Head of Translational Pharmacology & VP
  • Mr. Harold E. Brakewood (Age 59)
    Chief Business Officer

IMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price target for 2024?

8 Wall Street analysts have issued 1 year target prices for Immuneering's shares. Their IMRX share price targets range from $3.00 to $25.00. On average, they predict the company's share price to reach $15.50 in the next year. This suggests a possible upside of 436.3% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2024?

Immuneering's stock was trading at $7.35 at the beginning of 2024. Since then, IMRX shares have decreased by 60.7% and is now trading at $2.89.
View the best growth stocks for 2024 here
.

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IMRX earnings forecast
.

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) announced its quarterly earnings results on Friday, March, 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.06.

What ETF holds Immuneering's stock?

Range Cancer Therapeutics ETF holds 13,232 shares of IMRX stock, representing 1.36% of its portfolio.

When did Immuneering IPO?

Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Immuneering's major shareholders?

Immuneering's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.54%), Price T Rowe Associates Inc. MD (11.54%), Citadel Advisors LLC (7.10%), Vanguard Group Inc. (3.67%), Vanguard Group Inc. (3.67%) and Goldman Sachs Group Inc. (1.56%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Cormorant Asset Management, Lp, Harold Eugene Brakewood, Laurie Keating, Leah R Neufeld, Mallory Morales, Michael Bookman, Peter Feinberg and Scott Barrett.
View institutional ownership trends
.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners